EmpaMet 12.5 mg+1000 mg (Tablet)
Unit Price: ৳ 31.00 (4 x 8: ৳ 992.00)
Strip Price: ৳ 248.00
Medicine Details
Category | Details |
---|---|
Generic | Empagliflozin metformin hydrochloride |
Company | Nipro jmi pharma ltd |
Also available as |
Indications
- Treatment of adults with type 2 diabetes mellitus
- Adjunct to diet and exercise
- Insufficiently controlled on maximally tolerated dose of Metformin alone
- Combination with other medicinal products for diabetes
- Patients on combination of Empagliflozin and Metformin as separate tablets
Pharmacology
- Inhibitor of Sodium-Glucose Co-Transporter 2 (SGLT2)
- Reduces renal reabsorption of filtered glucose
- Lowers renal threshold for glucose
- Increases urinary glucose excretion
- Biguanide type oral antihyperglycemic drug
- Lowers basal and postprandial plasma glucose
- Does not produce hypoglycemia
- Decreases hepatic glucose production
- Decreases intestinal absorption of glucose
- Improves insulin sensitivity
Dosage & Administration
- Individualized based on effectiveness and tolerability
- Take twice daily with meals
- Dose escalation should be gradual
- Maximum recommended daily dose of Metformin Hydrochloride is 2000 mg and Empagliflozin is 25 mg
- Extended-release formulations available
- Dosage adjustment for renal impaired patients
- Not recommended for pediatric patients under 18 years of age
Interaction
- Co-administration with diuretics
- Co-administration with insulin or insulin secretagogues
- Effects on urine glucose test
- Drugs that reduce Metformin clearance
- Carbonic Anhydrase Inhibitors interaction
- Drugs affecting glycemic control
- Alcohol interaction
Contraindications
- Hypersensitivity to Empagliflozin and Metformin
- Acute metabolic acidosis
- Severe renal failure
- Conditions altering renal function
- Conditions causing tissue hypoxia
- Hepatic impairment
- Acute alcohol intoxication
Side Effects
- Urinary tract infection
- Female genital mycotic infections
- Diarrhea
- Nausea/vomiting
- Flatulence
- Abdominal discomfort
- Indigestion
- Asthenia
- Headache
- Hypoglycemia
- Thirst
- Taste disturbance
- Pruritus
- Rash
- Increased urination
- Increased serum lipids
- Volume depletion
- Urticaria
- Dysuria
- Increased blood creatinine
- Increased Haematocrit
- Diabetic ketoacidosis
Pregnancy & Lactation
- Potential risk to fetus
- Not recommended during breastfeeding
Precautions & Warnings
- Lactic Acidosis
- Hypotension
- Ketoacidosis
- Acute kidney injury & impairment in renal function
- Urosepsis, Pyelonephritis, Fournier’s gangrene & Genital mycotic infections
- Hypoglycemia
- Vitamin B12 Deficiency
- Increased LDL-C
- Macrovascular Outcomes
Overdose Effects
- No toxicity observed with high single doses of Empagliflozin
- No hypoglycemia observed with high Metformin doses
- Lactic acidosis potential with extremely high Metformin doses
- Treatment as appropriate to the patient's clinical status
- Haemodialysis for effective lactate and Metformin removal
Therapeutic Class
- Oral hypoglycemic preparations
Storage Conditions
- Keep below 30°C
- Protected from light & moisture
- Keep out of the reach of children
Related Brands
- Emazid M 12.5 mg+500 mg (Tablet) - eskayef-pharmaceuticals-ltd
- Emfogen M 12.5 mg+1000 mg (Tablet) - general-pharmaceuticals-ltd
- Emfogen M 12.5 mg+500 mg (Tablet) - general-pharmaceuticals-ltd
- Emfogen M 5 mg+1000 mg (Tablet) - general-pharmaceuticals-ltd
- Glifo-M XR 5 mg+1000 mg (Tablet (Extended Release)) - acme-laboratories-ltd